


AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Compounds of the general A~~ compound of formula
(I)



General Formula (I)

wherein:

X is O, NH, or N-CN;

n is the integer 0, 1, 2, or 3;

m is the integer 0, 1, 2, or 3;

R¹, R², R³, R⁴ independently represent cyano, halogen, hydrogen, hydroxyl, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₁-C₅ alkoxy, C₂-C₅ alkenyloxy, trifluoromethoxy, or cycloalkyloxy or R¹ and R² together as well as R² and R³ together or R³ and R⁴ together may form with the phenyl ring to which they are attached, a five, six or seven-membered ring containing one or two oxygen atoms which are separated by at least one carbon atom;

R⁵ represents hydrogen, C₁-C₅ alkyl, C₂-C₅ alkenyl, cycloalkyl, cycloalkyl-C₁-C₅ alkyl, -(CH₂)_m-O-C₁-C₅ alkyl, -(CH₂)_m-COOH, -(CH₂)_m-CO₂-C₁-C₅ alkyl, -(CH₂)_m-CONH₂, -(CH₂)_m-CONH-C₁-C₅ alkyl, -CON-(C₁-C₅ alkyl)₂, or -(CH₂)_m-N-C₁-C₅ alkyl;

R⁶ represents hydrogen, C₁-C₅ alkyl, cycloalkyl, or cycloalkyl-C₁-C₅ alkyl;

R⁷ represents hydrogen; C₁-C₅ alkyl; C₂-C₅ alkenyl; or mono-, di- or tri-substituted phenyl or phenyl-C₁-C₅ alkyl, whereby the substituents independently are C₁-C₅ alkyl, C₁-C₅ alkoxy, C₂-C₅ alkenyl or halogen; -(CH₂)_m-OH; -(CH₂)_m-O-C₁-C₅ alkyl; -(CH₂)_m-CO₂H; -(CH₂)_m-CO₂-C₁-C₅ alkyl; -(CH₂)_m-CONH₂; -(CH₂)_m-CONH-C₁-C₅ alkyl; or -CON-(C₁-C₅ alkyl)₂;

R⁸ represents unsubstituted phenyl; unsubstituted pyridyl; unsubstituted phenyl-C₁-C₅ alkyl; unsubstituted pyridyl-C₁-C₅ alkyl; or mono-, di- or tri-substituted phenyl, pyridyl, phenyl-C₁-C₅ alkyl or pyridyl-C₁-C₅ alkyl, whereby the substituents independently are C₁-C₅ alkyl, C₁-C₅ alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen; and

R⁹ represents C₁-C₅ alkyl, C₂-C₅ alkenyl, cycloalkyl, cycloalkyl-C₁-C₅ alkyl, unsubstituted phenyl-C₁-C₅ alkyl; or mono-, di- or tri-substituted phenyl or phenyl-C₁-C₅ alkyl, whereby the substituents independently are C₁-C₅ alkyl, C₁-C₅ alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen;

[[and]] or optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms, [[and]] or pharmaceutically acceptable salts thereof.

2. (Currently amended) ~~Compounds of the general~~ The compound of formula (I) according to claim 1, wherein n is the integer 0, m is the integer 0, ~~R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹~~ have the meaning given in the formula (I) above and X represents oxygen.

3. (Currently amended) ~~Compounds of the general~~ The compound of formula (I) according to claim 1, wherein n is the integer 0, m is the integer 0, R⁵ represents methyl, R⁶ represents phenyl, ~~R¹, R², R³, R⁴, R⁷, R⁸ and R⁹~~ have the meaning given in the formula (I) above and X represents oxygen.

4. (Currently amended) [[A]] The compound according to ~~any one of claims 1 to 3,~~ claim 1 selected from the group consisting of:

1-[1-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-3-(2-propyl-phenyl)-urea;

3-Biphenyl-2-yl-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-1-[1-phenyl-ethyl)urea;

3-(2-Ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-urea;

3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((S)-1-phenyl-ethyl)-urea;

3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((R)-1-phenyl-ethyl)-urea;

3-(2-Ethoxy-phenyl-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

3-(2-Ethoxy-phenyl-1-(2-methoxy-(R)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

(R)-2-{3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-ureido}-2-phenyl-acetamide;

(3-{1-[3-(Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl}-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethyl ester;

2-{3-[3-(2-Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureidomethyl]-2-oxo-2H-quinoxalin-1-yl}-acetamide;

1-Benzyl-3-(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea;

1-Benzyl-3-(2-ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-1-(1-phenyl-ethyl)-urea;

(S)-3-(2-Ethoxy-phenyl)-1-(3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-(1-phenyl-ethyl)-urea;

1-(6-Chloro-pyridin-3-ylmethyl)-3(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

(S)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

(R)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;

3-(2-Ethoxy-phenyl)-1-(2-hydroxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

3-(2-Ethoxy-phenyl)-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

3-(2-Ethoxy-phenyl)-1-(3-hydroxy-(S)-1-phenyl-propyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-((S)-2-phenyl-propyl)-urea;

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(3-trifluoromethyl-phenyl)-ethyl]-urea;

3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(4-trifluoromethyl-phenyl)-ethyl]-urea; and

N-(2-Ethoxy-phenyl)-*N'*-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-*N'*-1-phenyl-ethyl-cyanoguanidine.

5. (Currently amended) ~~Pharmaceutical compositions for the treatment of disorders which are associated with the role of orexin, comprising eating disorders and sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or~~

~~neurodegenerative disorders, containing~~ A pharmaceutical composition comprising one or more compounds of ~~any one of claims 1 to 4~~ claim 1, or a pharmaceutically acceptable salt thereof, and ~~usual a carrier materials and adjuvants~~ and/or adjuvant.

6. (Cancelled).

7. (Cancelled).

8. (Currently amended) A method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, ~~which comprises~~ said method comprising administering to a subject in need thereof a therapeutically effective amount of ~~[[a]] the compound as claimed in any one of claims 1 to 4~~ claim 1, or a pharmaceutically acceptable salt thereof.

9. (Currently amended) A process for ~~the manufacture of pharmaceutical compositions~~ manufacturing a pharmaceutical composition for the treatment of disorders associated with the role of orexin, eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, ~~containing one or more compounds as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, as active ingredients, which~~ said process comprises comprising mixing one or more active ingredient or ingredients compounds of claim 1 with a pharmaceutically acceptable excipients and adjuvants ~~in a manner known per se~~ excipient and/or adjuvant.

10. (Cancelled).

11. (Currently amended) A compound as described as an end-product in any one of examples 1 to 20.

12. (New) A pharmaceutical composition comprising one or more compounds of claim 4, or a pharmaceutically acceptable salt thereof, and a carrier and/or adjuvant.

13. (New) A method of treating or preventing diseases or disorders which are associated with a role of orexin and comprise eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, said method comprising administering to a subject in need thereof a therapeutically effective amount of the compound as claimed in claim 4, or a pharmaceutically acceptable salt thereof.

14. (New) A method of treating or preventing a disease or disorder associated with a role of orexin and selected from the group consisting of eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, said method comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1 in combination with an additional pharmacologically active compound comprising other orexin receptor antagonists, lipid lowering agents, anorectic agents, sleep inducing agents, and/or antidepressants.